Yahoo · Sep 18, 2026
Natera CEO Steven Chapman Sells 1,698 Shares for $545,000
The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.
NT
NASDAQ · NTRA
Natera, Inc.
Healthcare · Medical - Diagnostics & Research
$369.39
Up+$3.08 (+0.84%)
Updated Sep 20, 2026, 4:06 PM
SID Score
7.2/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 31.89B
- P/E ratio
- -102.52
- Dividend yield
- 0.00%
- 52-week range
- $157.43 – $369.69
- Volume
- 3.72M
- Avg. volume
- 1.34M
Price performance
NTRA price history
1M range · 19 trading sessions · Daily adjusted prices
NTRA closed at $369.39 after 19 trading sessions, up 12.72% for the selected period.
- Last close
- $369.39
- Period change
- +12.72%
- Period low
- $320.76
- Period high
- $369.39
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $365.78 | $369.69 | $358.90 | $369.39 | 3.72M |
| Sep 17, 2026 | $350.50 | $366.70 | $348.26 | $366.31 | 2.56M |
| Sep 16, 2026 | $350.18 | $357.145 | $343.275 | $345.34 | 1.43M |
| Sep 15, 2026 | $340.34 | $351.7799 | $338.82 | $350.78 | 1.78M |
| Sep 14, 2026 | $327.91 | $343.00 | $327.1509 | $341.79 | 1.04M |
| Sep 11, 2026 | $330.18 | $330.18 | $324.45 | $328.93 | 798.06K |
| Sep 10, 2026 | $324.92 | $331.185 | $320.65 | $326.14 | 1.07M |
| Sep 9, 2026 | $324.14 | $331.88 | $321.19 | $330.31 | 707.35K |
| Sep 8, 2026 | $326.29 | $331.3963 | $321.21 | $324.14 | 1.03M |
| Sep 4, 2026 | $323.92 | $329.05 | $323.42 | $328.18 | 968.22K |
| Sep 3, 2026 | $325.65 | $332.00 | $320.0101 | $327.67 | 711.94K |
| Sep 2, 2026 | $318.53 | $330.92 | $318.00 | $325.165 | 1.03M |
| Sep 1, 2026 | $320.99 | $325.00 | $318.355 | $320.76 | 1.21M |
| Aug 31, 2026 | $320.95 | $325.65 | $316.00 | $321.96 | 1.33M |
| Aug 28, 2026 | $335.28 | $339.30 | $325.66 | $326.26 | 833.87K |
| Aug 27, 2026 | $337.46 | $343.18 | $334.45 | $338.70 | 731.37K |
| Aug 26, 2026 | $333.29 | $340.96 | $333.29 | $338.45 | 1.09M |
| Aug 25, 2026 | $330.31 | $337.12 | $325.98 | $336.71 | 1.73M |
| Aug 24, 2026 | $328.40 | $331.91 | $321.59 | $327.72 | 1.22M |
Latest NTRA news
The latest Smart Investors Daily articles mentioning NTRA.
Stock researchCompany · Overview
NTRA research
Overview
Company profile and research snapshot.
Company profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $232.00
- Implied upside
- —
- Analysts
- 27
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Buy | — |
| Sep 8, 2026 | Rothschild & Co | Buy | — |
| Aug 13, 2026 | Citigroup | Buy | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| Aug 12, 2026 | Stephens & Co. | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 18, 2026
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
AUSTIN, Texas, September 18, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. Natera and its collaborators presented four abstracts, including two oral presentations.
Yahoo · Sep 17, 2026
Natera Stock Has Excellent Technical ‘DNA’ as NTRA Sets a New All-Time High
Natera (NTRA) demonstrates strong technical momentum, with shares hitting a new all-time high. Shares are up more than 105% over the past year. Valuation concerns persist, as Morningstar sees NTRA as 33% overvalued and multiple analysts rate it a “Hold” despite bullish technicals. I recommend holding NTRA while it trades...
Yahoo · Sep 9, 2026
3 Reasons Investors Love Natera (NTRA)
What a time it’s been for Natera. In the past six months alone, the company’s stock price has increased by a massive 59.9%, reaching $328.13 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
